Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Proximal lower limb muscle weakness and Proximal upper limb muscle weakness; and very common findings: Progressive muscle deterioration (muscular dystrophy), Neck muscle weakness, and EMG: myopathic abnormalities. 26 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 16 | Achilles tendon contracture, Weakness of facial musculature, Proximal lower limb muscle weakness |
JAG2 encodes jagged canonical Notch ligand 2 (1,238 aa). Putative Notch ligand involved in the mediation of Notch signaling. Involved in limb development Highest expression in Pituitary (56.8 TPM) and Skin Not Sun Exposed Suprapubic (51.0 TPM).
Muscular dystrophy, limb-girdle, autosomal recessive 27 is associated with mutations in the JAG2 gene on chromosome 14.
The JAG2 protein participates in NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind JAG2, NOTCH1 HD domain mutants bind JAG2, and NOTCH1 PEST domain mutants bind JAG2 pathways.
JAG2 is classified as a druggable target (Growth Factor category) with score 0.0.
Genetic testing for JAG2 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 always present features, 3 very common features, 9 common features.
No clinical trials have been registered for muscular dystrophy, limb-girdle, autosomal recessive 27.
5 publications have been identified in PubMed for muscular dystrophy, limb-girdle, autosomal recessive 27. Research spans Epidemiology / Natural History (40%), Gene Therapy / Novel Therapeutics (40%), and Case Report / Case Series (20%).
Sakhaei A (2026). [PMID: 41721539](https://pubmed.ncbi.nlm.nih.gov/41721539/). *Cell journal*. [Case Report / Case Series]
Baine S (2026). [PMID: 41194675](https://pubmed.ncbi.nlm.nih.gov/41194675/). *Human gene therapy*. [Gene Therapy / Novel Therapeutics]
Guérémy A (2026). [PMID: 41943552](https://pubmed.ncbi.nlm.nih.gov/41943552/). *Muscle Nerve*. [Epidemiology / Natural History]
Mathur P (2025). [PMID: 39925440](https://pubmed.ncbi.nlm.nih.gov/39925440/). *Global medical genetics*. [Epidemiology / Natural History]
Anwar S (2025). [PMID: 39967852](https://pubmed.ncbi.nlm.nih.gov/39967852/). *Molecular therapy. Nucleic acids*. [Gene Therapy / Novel Therapeutics]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 12:26 PM UTC
Online Mendelian Inheritance in Man
Brain and nerves | 5 | Mild intellectual disability, Spinal rigidity, Delayed speech and language development |
Arms and legs | 4 | Proximal lower limb muscle weakness, Proximal upper limb muscle weakness, Distal upper limb muscle weakness |
Bones and joints | 3 | Skeletal muscle atrophy, Sideways curvature of the spine (scoliosis), Skeletal muscle hypertrophy |
Lab test results | 1 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration) |
Head and neck | 1 | Weakness of facial musculature |
Eyes | 1 | Ptosis |
Heart and blood vessels | 1 | Heart muscle disease (cardiomyopathy) |